What Genvor does

Genvor Incorporated (OTCQB: GNVR) is an AI-accelerated peptide design company operating across two verticals: sustainable agriculture and consumer human health and wellness. Its core technology is the proprietary BioCypher Algorithm, which combines computational biology, molecular modeling, reinforcement learning, and evolutionary algorithms to generate and optimize peptide sequences. The platform has produced a library of over 50,000 designed peptides with 24 proprietary peptides in active use, spanning antimicrobial peptides (AMPs), C-terminally encoded peptides (CEPs), nutrient-enhancing peptides (NEPs), insecticidal peptides, and recovery/performance peptides (RPPs). The company is headquartered in Woodland, California, where it opened a new laboratory in late 2025 to support R&D and international field trials.

Genvor monetizes through a licensing-first business model. In agriculture, it licenses transgenic seed traits (corn, soybeans, cotton), biological fungicide sprays (greenhouse and specialty crops), and Designer Bio-Stimulant Peptides (DBSPs) to Tier-1 agricultural companies, with revenue from milestone payments, fee reimbursements, and royalties tied to product performance. In human health, it plans to license peptide candidates to partners such as Canlab International (anticipated ~$1M annual payments or ~11% royalties per peptide category), pursue DTC e-commerce, and enter specialty retail for OTC nasal-delivery wellness products targeting recovery, performance, anti-aging, and daily wellness. Its IP portfolio includes 5 issued U.S. patents and international filings in Canada, Mexico, and China through 2038, supported by a 7+ year USDA CRADA.

As of Q4 2025 the company reported zero revenue and a reduced operating loss of $562,655 (88.7% lower YoY). It is publicly listed on OTCQB, has raised limited disclosed capital (a $425K round in 2025), has explicitly flagged the need to raise additional capital to continue as a going concern, and is preparing for commercial launches including its first corn AMP trait and a portfolio of ~5 wellness peptide candidates in 2026.

Name

Genvor

Legal name

Genvor Incorporated

Website

https://genvor.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Genvor (OTCQB: GNVR) is an AI-accelerated peptide design company that licenses antimicrobial, nutrient-enhancing, and recovery peptides to Tier-1 agricultural partners and consumer wellness companies via its proprietary BioCypher Algorithm and a licensing-first go-to-market model.

Ownership category

akta.pro rank

Product category

Agricultural Biotechnology

NAICS

Pesticide and Other Agricultural Chemical Manufacturing (32532), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Agricultural Chemicals (2870), Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Biostimulants & Plant Health Biologicals (Microbial/Non-microbial) (AFABAEAK)

akta.pro secondary industries

Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine) (AFAJAKAG), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Peptide design platform
• Agricultural crop protection
• Biological fungicide sprays
• Transgenic seed traits
• Wellness peptide products

Headquarters

HQ city

Henderson

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Others

Revenue model

1. Agricultural Licensing: Capital-efficient licensing model enabling Tier-1 agricultural partners to access validated peptide technology with protected market rights. The company licenses transgenic seed traits, biological fungicide sprays, and bio-stimulant peptides to agricultural companies. Licensing fees include fee reimbursements, milestone-based payments, and royalty-based income tied to product performance.
2. Wellness Product Royalties: Royalty-based participation on net sales of consumer peptide products. For each peptide category, Genvor anticipates royalty-based participation of approximately 11% on net sales, subject to future definitive agreements with partners such as Canlab International.
3. Wellness Development Payments: Potential annual payments of approximately $1 million per peptide category under the Canlab International agreement, subject to future definitive agreements. Development of approximately five peptide candidates planned for 2026 with roadmap to expand to twenty or more.
4. OTC Consumer Wellness Products: Direct-to-consumer and specialty retail sales of OTC peptide wellness products including nasal spray delivery for recovery, performance, anti-aging, and daily wellness. Products positioned as non-prescription OTC wellness items.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Genvor develops and commercializes AI-designed peptide classes for two end markets: sustainable agriculture and human health and wellness. In agriculture, it licenses Antimicrobial Peptides, C-terminally Encoded Peptides, Nutrient Enhancing Peptides, and Insecticidal Peptides to global seed, crop protection, and animal-feed partners for use in biological fungicide sprays, transgenic seed traits, and designer bio-stimulants. In human health and wellness, it is developing Recovery and Performance Peptides and Wellness and Anti-Aging Peptides, delivered via nasal spray and OTC formats in partnership with US distributors and MENA-region licensees.

Product overview

Genvor offers a unified peptide platform centered on its proprietary BioCypher Algorithm — an AI-accelerated design engine that generates targeted peptide solutions across two market verticals: sustainable agriculture and human health & wellness. The platform produces three core peptide classes (Antimicrobial Peptides/AMPs, C-terminally Encoded Peptides/CEPs, and Nutrient Enhancing Peptides/NEPs), plus Insecticidal Peptides for agriculture and Recovery & Performance Peptides (RPPs) and Wellness & Anti-Aging Peptides for human health. These are deployed through multiple delivery modes: Biological Fungicide Sprays (for specialty crops), Seed Trait Licensing (encoded into row crop seeds), and Designer Bio-Stimulant Peptides (DBSPs, for foliar/soil application), and nasal spray delivery for human wellness products. The technology core (BioCypher) serves as the single innovation engine underpinning all products and delivery modes.

Differentiator

Problem solved

Functional benefit

Products and services

• Antimicrobial Peptides (AMPs) AI-designed antimicrobial peptides that suppress crop-damaging fungi and pathogens; licensed to seed and crop protection partners for deployment as biological fungicide sprays, transgenic seed traits, and post-harvest treatments.
• C-terminally Encoded Peptides (CEPs) Plant-derived signaling peptides used to regulate nutrient use, root development, and stress response; licensed to seed and bio-stimulant partners for row-crop and specialty applications.
• Nutrient Enhancing Peptides (NEPs) Peptides that improve nutrient uptake and utilization in plants and animals; positioned for licensing to animal feed manufacturers and to crop input formulators seeking feed- and fertilizer-efficiency gains.
• Insecticidal Peptides Peptide-based insect control agents offered as an alternative to conventional chemical insecticides; licensed to crop protection partners addressing pest resistance and regulatory phase-outs.
• Recovery & Performance Peptides (RPPs) Human-health peptides targeted at recovery, energy, and physical performance; co-developed and distributed through Canlab International and OTC licensees in nasal-spray and related delivery formats.
• Wellness & Anti-Aging Peptides Human-health peptides positioned for daily wellness and anti-aging use; intended for nasal-spray and OTC formats distributed via Canlab International and MENA-region licensees.
• Biological Fungicide Spray Peptides AMP-based peptide formulations designed for spray application on greenhouse, hydroponic, and specialty crops; supplied through licensing partners as a residue-free alternative to conventional fungicides.
• Transgenic Seed Trait Peptides Peptide-encoding transgenes, including AGM182 and D4E1, licensed to seed companies for incorporation into row-crop and specialty-crop genetics to confer built-in antifungal protection.
• Designer Bio-Stimulant Peptides (DBSPs) Custom-designed peptide bio-stimulants for regenerative and sustainable farming systems; positioned for licensing to bio-stimulant and specialty fertilizer partners.

Quantifiable outcome

• 72% reduction in fungal growth and 98% reduction in aflatoxin contamination in corn trials with transgenic peptide AGM182
• +4 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Five partnerships are on record, tiered flagship and core.

• Canlab InternationalflagshipStrategic or Co-development Partner · 14 April 2026Non-binding Memorandum of Understanding to collaborate on developing, manufacturing, and commercializing a portfolio of novel peptide candidates targeting wellness markets including weight management, anti-aging, and tissue repair. Parties plan to initiate development of approximately five peptide candidates in 2026 with roadmap to expand to twenty or more. Leverages Canlab's manufacturing capabilities and distribution network of over 5,000 physicians and 500 medical spas. For each peptide category, Genvor anticipates potential annual payments of approximately $1 million or royalty-based participation of approximately 11% on net sales, subject to future definitive agreements.
• Tuskegee UniversitycoreStrategic or Co-development Partner · 2 December 2025Teaming agreement with Tuskegee University to collaborate on peptide research and sustainable crop protection technologies. Partnership provides Genvor access to Tuskegee's research facilities and academic talent to accelerate innovation and validation of biological ingredients for agriculture. The collaboration aims to accelerate innovation in biological manufacturing and crop resilience through joint research, testing, and funding support.
• B2i DigitalcoreGTM or Marketing Partner · 27 November 2025Partnership with B2i Digital as a Featured Company to expand investor awareness of Genvor's AI-accelerated peptide platform and sustainable agricultural solutions. The collaboration leverages B2i Digital's multi-channel digital marketing campaigns targeting investors interested in biological solutions for agriculture, highlighting Genvor's progress in developing sustainable crop protection technologies and its intellectual property portfolio.
• Bayer Crop ScienceflagshipStrategic or Co-development Partner · 1 January 2024Bayer's Golden Ticket award granted in 2024, providing one year of fully funded access to LifeHub California @AgStart innovation incubator. Includes advanced lab space, equipment, infrastructure, and mentorship from Bayer's Crop Science innovation team. The partnership supports advancement of peptide-based crop protection with access to lab space, technical mentorship, and commercialization pathways. Bayer's LifeHub California is located at AgStart. Bayer coverage includes full cost of Genvor's access to lab space, equipment, and infrastructure at the incubator.
• United States Department of Agriculture (USDA)coreStrategic or Co-development Partner · 1 January 2018Collaborative Research and Development Agreement (CRADA) with the USDA targeting aflatoxin-producing pathogens in corn, supporting the development of disease-resistant crops and advancing peptide commercialization. Provides access to USDA-managed field trials and greenhouse testing, early alignment with EPA and USDA regulatory frameworks, validation of peptide efficacy in real-world agricultural settings, and a streamlined path to market through scientific collaboration. The partnership has supported 7+ years of joint research and development.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• AgBiome: AgBiome develops microbial-based crop protection and plant health products, directly comparable to Genvor's biological crop protection approach. Both companies target sustainable agriculture with biological alternatives to chemical pesticides, though AgBiome focuses on microbes while Genvor uses synthetic peptides.
• Pivot Bio: Pivot Bio develops microbial nitrogen-fixing solutions for cereal crops, comparable to Genvor's Nutrient Enhancing Peptides for improved nutrient uptake in plants. Both companies are agricultural biologicals innovators targeting Tier-1 seed and fertilizer partners with sustainability-focused solutions.
• Indigo Ag: Indigo Ag develops microbial seed treatments and biostimulants to improve crop yield and stress tolerance. Compares to Genvor's Designer Bio-Stimulant Peptides (DBSPs) and seed trait licensing model, both targeting regenerative agriculture outcomes through biological inputs.
• Protagonist Therapeutics: Protagonist Therapeutics is a clinical-stage peptide therapeutics company developing targeted peptide drugs, directly comparable to Genvor's peptide platform for human health applications. Connection is reinforced by Genvor's new CFO Donald Kalkofen, who previously served as Protagonist's CFO during its IPO.
• Alpha Cognition: Alpha Cognition is a peptide-based pharmaceutical company developing therapies for neurodegenerative diseases, comparable to Genvor's therapeutic peptide applications for human health. Connection reinforced by Genvor's CFO Donald Kalkofen who previously served as Alpha Cognition's CFO through its public listing process.

Broad incumbents

• Novonesis (formerly Novozymes): Novonesis is a global leader in enzyme and microbial solutions for agriculture, animal feed, and human health. Comparable as a broad incumbent offering biological alternatives to chemicals, though with much larger scale, established commercial channels, and a broader portfolio spanning multiple of Genvor's target applications.
• Valagro: Valagro is a global leader in biostimulants and specialty plant nutrition products, now owned by Syngenta. Directly comparable to Genvor's Designer Bio-Stimulant Peptides (DBSPs) and bio-stimulant business model targeting specialty and row crops, but with established commercial scale.

Emerging players

• Invaio Sciences: Invaio Sciences develops biological solutions for crop health and pest management, partially overlapping with Genvor's antimicrobial and insecticidal peptide portfolio. Both companies target agricultural biologicals with novel delivery mechanisms, though Invaio emphasizes precision delivery systems over peptide design.
• BioConsortia: BioConsortia develops microbial and biological products for crop yield and stress improvement, comparable to Genvor's agricultural biologicals approach. Both companies target Tier-1 ag partners for licensing and commercialization of novel biological inputs.
• Pluton Biosciences: Pluton Biosciences is a microbial discovery company developing biological crop protection products. Comparable to Genvor's approach of using AI-accelerated discovery to generate biological alternatives to chemical pesticides, though focused on microbial rather than peptide-based solutions.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genvor